» Articles » PMID: 24971869

Association Between Urinary C-telopeptide Fragments of Type II Collagen and Knee Structure in Middle-aged Women Without Clinical Knee Disease

Overview
Date 2014 Jun 28
PMID 24971869
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: There is evidence for an association between levels of urinary C-telopeptide fragments of type II collagen (uCTX-II) and risk of knee osteoarthritis (OA). The aim of this cohort study was to examine the association between uCTX-II levels and knee cartilage and bone changes in middle-aged women without clinical knee disease.

Design: 140 women, aged 40-67 years, with no significant knee pain, knee injury or any forms of arthritis, underwent knee magnetic resonance imaging (MRI) at baseline and 2 years later. Cartilage volume, cartilage defects, tibial plateau bone area and bone marrow lesions (BMLs) were measured using validated methods. Baseline uCTX-II was measured using enzyme-linked immunosorbent assay (ELISA).

Results: For every one unit (natural logarithm transformed) increase in baseline uCTX-II level, there was an increase in the prevalence of medial tibiofemoral cartilage defects (Odds ratio (OR) 4.36, 95% confidence interval (CI) 1.58-12.04), medial (80.2 mm(2), 95% CI 9.3-151.1) and lateral (86.0 mm(2), 95% CI 33.3-138.7) tibial plateau bone area, and the prevalence of lateral tibiofemoral BMLs (OR 10.62, 95% CI 1.82-61.85). Baseline uCTX-II levels were not significantly associated with baseline tibial cartilage volume or changes in knee cartilage volume or defects or bone area over 2 years, although there was a trend for the deterioration of medial tibiofemoral BMLs (P = 0.06).

Conclusion: In middle-aged women without clinical knee disease, higher uCTX-II levels were associated with early detrimental structural changes at the knee (cartilage defects, tibial bone expansion and BMLs) at baseline but not over 2 years. Further work will be needed to determine its sensitivity to change and whether it predicts disease progression over longer time periods.

Citing Articles

Association of biochemical markers with bone marrow lesion changes on imaging-data from the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium.

Yu S, Deveza L, Kraus V, Karsdal M, Bay-Jensen A, Collins J Arthritis Res Ther. 2024; 26(1):30.

PMID: 38238803 PMC: 10795356. DOI: 10.1186/s13075-023-03253-x.


Clinically Relevant Molecular Biomarkers for Use in Human Knee Osteoarthritis: A Systematic Review.

Convill J, Tawy G, Freemont A, Biant L Cartilage. 2020; 13(1_suppl):1511S-1531S.

PMID: 32680434 PMC: 8808945. DOI: 10.1177/1947603520941239.


The relationship between urinary C-Telopeptide fragments of type II collagen, knee joint load, pain, and physical function in individuals with medial knee osteoarthritis.

Selistre L, Helena Goncalves G, Vasilceac F, Serrao P, Nakagawa T, Petrella M Braz J Phys Ther. 2020; 25(1):62-69.

PMID: 32151525 PMC: 7817859. DOI: 10.1016/j.bjpt.2020.02.002.


Increased Urinary Concentration of C-Terminal Telopeptide of Type II Collagen and Pain by Radiographic Grade in Women with Knee Osteoarthritis in Northeastern Mexico: A Cross-Sectional Study.

Garcia-Alvarado F, Gonzalez-Martinez M, Jaramillo-Rodriguez Y, Delgado-Aguirre H Biores Open Access. 2020; 9(1):7-12.

PMID: 32064175 PMC: 7019197. DOI: 10.1089/biores.2019.0003.


Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study.

Kuah D, Sivell S, Longworth T, JAMES K, Guermazi A, Cicuttini F J Transl Med. 2018; 16(1):49.

PMID: 29510712 PMC: 5840781. DOI: 10.1186/s12967-018-1420-z.